KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Inventory (2020 - 2025)

Historic Change in Inventory for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to -$5.9 million.

  • Esperion Therapeutics' Change in Inventory fell 3572.25% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.4 million, marking a year-over-year decrease of 80.23%. This contributed to the annual value of $28.9 million for FY2024, which is 510.81% down from last year.
  • Per Esperion Therapeutics' latest filing, its Change in Inventory stood at -$5.9 million for Q3 2025, which was down 3572.25% from $15.1 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Change in Inventory ranged from a high of $15.1 million in Q2 2025 and a low of -$6.4 million during Q2 2022
  • Moreover, its 5-year median value for Change in Inventory was $4.8 million (2025), whereas its average is $4.9 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Change in Inventory plummeted by 27432.14% in 2022, and later surged by 173993.61% in 2023.
  • Esperion Therapeutics' Change in Inventory (Quarter) stood at $422000.0 in 2021, then surged by 1240.28% to $5.7 million in 2022, then soared by 150.85% to $14.2 million in 2023, then increased by 1.42% to $14.4 million in 2024, then plummeted by 141.19% to -$5.9 million in 2025.
  • Its last three reported values are -$5.9 million in Q3 2025, $15.1 million for Q2 2025, and $4.8 million during Q1 2025.